After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A TargetBenzinga • 12/16/19
Amarin Receives FDA Approval of VASCEPA® (icosapent ethyl) to Reduce Cardiovascular RiskGlobeNewsWire • 12/13/19
Is Amarin Corporation (AMRN) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research • 12/11/19
Amarin's Litigation Landscape: Mostly Successful, Clearing The Field For A DecadeSeeking Alpha • 12/10/19
European Medicines Agency Accepts for Review Marketing Authorization Application for Amarin’s Icosapent Ethyl (Vascepa®) for Reduction of Cardiovascular Risk in High-Risk Patients, as Reflected in REDUCE-IT® StudyGlobeNewsWire • 12/02/19